3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
5
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Giant Cell Tumor of Bone
1
Ganglioneuroblastoma
1
Carcinoma
1
Brain Neoplasms
1
Alzheimer Disease
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Transurethral Resection of Bladder
×
Clear all
NCT07067749
2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3
Recruiting
92 enrolled